{"id":"placebo-in-combination-with-metformin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3-10","effect":"Metallic taste"},{"rate":"10-30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1703","moleculeType":"Small molecule","molecularWeight":"165.63"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo in combination with metformin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:29:31.599856+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:29:47.683701+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:29:37.543805+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo in combination with metformin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:29:38.015619+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:29:39.583239+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1703/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:29:39.250410+00:00"}},"_dailymed":null,"aiSummary":"Placebo in combination with metformin, marketed by Campus Bio-Medico University, holds a unique position in the diabetes management market. The key composition patent is set to expire in 2028, providing a period of exclusivity that could protect current market share. However, the lack of a defined mechanism and primary indication poses a significant risk, potentially limiting its therapeutic value and competitive edge.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance with no direct molecular target or biological activity. In this combination, metformin is the active agent that improves insulin sensitivity and reduces hepatic glucose production. The placebo component serves as a control or comparator in clinical research settings.","oneSentence":"Placebo has no active pharmacological mechanism; when combined with metformin, the therapeutic effect is entirely attributable to metformin's action on glucose metabolism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:09.273Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:29:47.683781+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Type 2 diabetes mellitus (metformin component)"}]},"trialDetails":[{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT03514108","phase":"PHASE4","title":"DANHEART (H-HeFT and Met-HeFT)","status":"COMPLETED","sponsor":"Henrik Wiggers","startDate":"2018-03-01","conditions":"Heart Failure, Diabetes","enrollment":1100},{"nctId":"NCT07395895","phase":"PHASE3","title":"Effect of Metformin Iontophoresis on Knee Osteoarthritis in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Badr University","startDate":"2026-03-01","conditions":"Osteoarthritis in Postmenopausal Women","enrollment":68},{"nctId":"NCT00971243","phase":"PHASE2","title":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT02924064","phase":"PHASE3","title":"Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-09","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT04221750","phase":"PHASE3","title":"Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-05-14","conditions":"Frailty, Sarcopenic Obesity, Aging","enrollment":114},{"nctId":"NCT07303127","phase":"NA","title":"Combination of Bitter Melon Extract and Snakehead Fish Powder to Reduce Glycaemia in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Universitas Muhammadiyah Surakarta","startDate":"2021-06-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":80},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05131828","phase":"PHASE2","title":"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2022-03-08","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT06571591","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2024-08-27","conditions":"T2DM","enrollment":582},{"nctId":"NCT04578652","phase":"PHASE3","title":"Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2021-10-22","conditions":"Obesity, Childhood, Insulin Resistance","enrollment":90},{"nctId":"NCT07026968","phase":"PHASE3","title":"A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-06-20","conditions":"Type 2 Diabetes","enrollment":815},{"nctId":"NCT07093476","phase":"PHASE3","title":"Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-07-18","conditions":"T2DM, Diabete Type 2, DM","enrollment":171},{"nctId":"NCT05243654","phase":"PHASE2","title":"Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy","status":"RECRUITING","sponsor":"Oxford University Clinical Research Unit Indonesia","startDate":"2022-10-01","conditions":"Leprosy, Leprosy, Multibacillary, Neglected Tropical Diseases","enrollment":166},{"nctId":"NCT06649773","phase":"PHASE3","title":"The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Type 2 Diabetes","enrollment":137},{"nctId":"NCT07076056","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-10-27","conditions":"Type 2 Diabetes","enrollment":230},{"nctId":"NCT07057271","phase":"PHASE3","title":"A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues","status":"COMPLETED","sponsor":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","startDate":"2021-05-27","conditions":"Type 2 Diabetes Mellitus - Poor Control","enrollment":464},{"nctId":"NCT01135433","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-05-15","conditions":"Type 2 Diabetes Mellitus","enrollment":168},{"nctId":"NCT01117584","phase":"PHASE2","title":"A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-04-06","conditions":"Type 2 Diabetes Mellitus","enrollment":343},{"nctId":"NCT05949008","phase":"PHASE4","title":"Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-11-22","conditions":"NIDDM, Obesity","enrollment":150},{"nctId":"NCT06860841","phase":"PHASE4","title":"Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Campus Bio-Medico University","startDate":"2025-01-10","conditions":"Type 2 Diabetes, Overweight and Obese Adults","enrollment":16},{"nctId":"NCT04998032","phase":"PHASE2, PHASE3","title":"A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)","status":"COMPLETED","sponsor":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","startDate":"2021-10-12","conditions":"Type2 Diabetes","enrollment":620},{"nctId":"NCT02794792","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-05-11","conditions":"Type 2 Diabetes Mellitus","enrollment":268},{"nctId":"NCT01505426","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-11-28","conditions":"Type II Diabetes Mellitus","enrollment":171},{"nctId":"NCT01734785","phase":"PHASE3","title":"Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-02-08","conditions":"Diabetes Mellitus, Type 2","enrollment":607},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT05505994","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-09-28","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":340},{"nctId":"NCT05653895","phase":"NA","title":"Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2022-12-07","conditions":"PCOS","enrollment":120},{"nctId":"NCT05878535","phase":"PHASE2","title":"METFORMIN FOR ATRIAL FIBRILLATION","status":"UNKNOWN","sponsor":"Arab Contractors Medical Centre","startDate":"2024-06-01","conditions":"Atrial Fibrillation","enrollment":770},{"nctId":"NCT06203275","phase":"PHASE3","title":"The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"aya ramadan ashmawy sarhan","startDate":"2024-01","conditions":"Diabetes Mellitus, Type 2","enrollment":44},{"nctId":"NCT02434744","phase":"PHASE2","title":"Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2015-04","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT00871936","phase":"PHASE2","title":"A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2009-04","conditions":"Type 2 Diabetes","enrollment":82},{"nctId":"NCT04649502","phase":"PHASE3","title":"Metformin for the Treatment of Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"K.R. van Straalen","startDate":"2021-01-25","conditions":"Hidradenitis Suppurativa","enrollment":62},{"nctId":"NCT06007014","phase":"NA","title":"Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2023-10-31","conditions":"Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients, Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect, 128 Patients Were Randomly Assigned 1:1","enrollment":128},{"nctId":"NCT04504396","phase":"PHASE3","title":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-06-23","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":620},{"nctId":"NCT05054842","phase":"PHASE3","title":"Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-12-06","conditions":"Type 2 Diabetes","enrollment":174},{"nctId":"NCT03765359","phase":"PHASE4","title":"Metformin Use to Improve Pregnancy Outcome in Women With Type 1 Diabetes.","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2019-08-05","conditions":"Diabetic Pregnancy, Insulin Resistance, Type1diabetes","enrollment":101},{"nctId":"NCT05601336","phase":"PHASE3","title":"of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2022-01-15","conditions":"PCO","enrollment":200},{"nctId":"NCT03907423","phase":"NA","title":"Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2019-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT04075110","phase":"EARLY_PHASE1","title":"Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-07-01","conditions":"Obesity; Endocrine; Diabetes Type 2","enrollment":100},{"nctId":"NCT04634500","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-11-18","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":200},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05226897","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2021-07-12","conditions":"Type 2 Diabetes","enrollment":256},{"nctId":"NCT03525028","phase":"NA","title":"A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis","status":"UNKNOWN","sponsor":"Tianjin Medical University","startDate":"2018-11-01","conditions":"Uveitis, Metformin, Glucocorticoid","enrollment":138},{"nctId":"NCT04047537","phase":"NA","title":"Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes","status":"TERMINATED","sponsor":"Pendulum Therapeutics","startDate":"2019-08-06","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT03761134","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":377},{"nctId":"NCT05296044","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2022-04-05","conditions":"Type 2 Diabetes Mellitus","enrollment":245},{"nctId":"NCT04356742","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-05-26","conditions":"Type 2 Diabetes","enrollment":198},{"nctId":"NCT02491333","phase":"PHASE3","title":"The RCT of Acupuncture on PCOS Combined With IR","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2015-08","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":342},{"nctId":"NCT05101135","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2021-11-17","conditions":"Type 2 Diabetes Mellitus","enrollment":256},{"nctId":"NCT01775813","phase":"PHASE4","title":"The Health Influences of Puberty (HIP) Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":"Obesity, Insulin Resistance, Gonadal Dysfunction","enrollment":104},{"nctId":"NCT05159882","phase":"PHASE3","title":"Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM","status":"UNKNOWN","sponsor":"Newsoara Biopharma Co., Ltd.","startDate":"2021-04-15","conditions":"T2DM","enrollment":390},{"nctId":"NCT04170998","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-01-02","conditions":"Type2 Diabetes","enrollment":283},{"nctId":"NCT04182321","phase":"NA","title":"Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Fu-Sheng Wang","startDate":"2020-03-13","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT03770728","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT04659915","phase":"PHASE4","title":"Counteracting Deleterious Metabolic Glucocorticoid Effects With Metformin","status":"COMPLETED","sponsor":"Eleonora Seelig","startDate":"2021-02-25","conditions":"Glucocorticoid Effect","enrollment":19},{"nctId":"NCT03243851","phase":"PHASE2","title":"Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma","status":"COMPLETED","sponsor":"Yong-Kil Hong","startDate":"2016-11-21","conditions":"Glioblastoma","enrollment":81},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT04218734","phase":"PHASE3","title":"A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-14","conditions":"Type 2 Diabetes Mellitus","enrollment":214},{"nctId":"NCT03066830","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-02-24","conditions":"Type 2 Diabetes Mellitus","enrollment":507},{"nctId":"NCT03332771","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":954},{"nctId":"NCT01210911","phase":"PHASE2","title":"Metformin Combined With Chemotherapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2010-08","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT03751657","phase":"PHASE2","title":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":247},{"nctId":"NCT04268563","phase":"PHASE1, PHASE2","title":"Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-10","conditions":"Polycystic Ovary Syndrome, Infertility, ART","enrollment":80},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":3118},{"nctId":"NCT04667143","phase":"PHASE3","title":"Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-01","conditions":"Diabetes Mellitus, Type II","enrollment":760},{"nctId":"NCT02179788","phase":"PHASE1, PHASE2","title":"Metformin to Augment Low Milk Supply (MALMS) Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-06","conditions":"Low Milk Supply, Pre-diabetes, Insulin Resistance","enrollment":15},{"nctId":"NCT01528254","phase":"PHASE4","title":"VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":"Type 2 Diabetes Mellitus","enrollment":2004},{"nctId":"NCT03349684","phase":"PHASE3","title":"Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":287},{"nctId":"NCT03851432","phase":"PHASE3","title":"Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin","status":"UNKNOWN","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2019-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":390},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT03317028","phase":"PHASE2","title":"CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Center Laboratories, Inc.","startDate":"2017-10-10","conditions":"T2DM With Inadequate Glycemic Control","enrollment":201},{"nctId":"NCT04390295","phase":"PHASE3","title":"Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-11-02","conditions":"Type 2 Diabetes Mellitus","enrollment":450},{"nctId":"NCT03419624","phase":"PHASE3","title":"The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-02-19","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":13},{"nctId":"NCT02897349","phase":"PHASE3","title":"Linagliptin Add-on to Insulin Background Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-30","conditions":"Diabetes Mellitus, Type 2","enrollment":206},{"nctId":"NCT03893422","phase":"NA","title":"Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pendulum Therapeutics","startDate":"2017-10-22","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT04255238","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2020-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":468},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT03444584","phase":"PHASE2","title":"Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Type 2 Diabetes Mellitus","enrollment":49},{"nctId":"NCT04141163","phase":"PHASE1, PHASE2","title":"Metformin in Patients With Fragile X","status":"UNKNOWN","sponsor":"Rowan University","startDate":"2019-10-29","conditions":"Fragile X Syndrome","enrollment":40},{"nctId":"NCT02308228","phase":"EARLY_PHASE1","title":"Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)","status":"COMPLETED","sponsor":"Philip Kern","startDate":"2015-01-14","conditions":"Aging","enrollment":109},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT02305381","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-12-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":397},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02470039","phase":"PHASE2","title":"Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-06-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT02005419","phase":"PHASE2","title":"Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection","status":"COMPLETED","sponsor":"Xian-Jun Yu","startDate":"2013-12","conditions":"Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT01523639","phase":"PHASE2","title":"A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis","status":"TERMINATED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2012-04","conditions":"Colorectal Cancer, Steatohepatitis","enrollment":8},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1703"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo in combination with metformin","genericName":"Placebo in combination with metformin","companyName":"Campus Bio-Medico University","companyId":"campus-bio-medico-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:29:47.683781+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}